The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older: A Systematic Review
Current Oncology · 31.03.2026 · 33 (4) · 199
DOI: 10.3390/curroncol33040199 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Current Oncology, online erschienen am 31.03.2026. Verfasst von Alexandria Bennett und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON K1G 5Z3, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Early Detection of Cancer. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Public Health Agency of Canada.
Abstract (Originalsprache)
Given ongoing uncertainty about the benefits and harms of prostate-specific antigen (PSA) screening, this systematic review updates the evidence to inform guideline recommendations for adults aged ≥ 18 years in primary care. We searched multiple bibliographic databases from inception to 30 May 2022, with an update on 24 July 2024, for randomized controlled trials (RCTs) and comparative observational studies evaluating PSA-based screening with or without adjunctive technologies such as magnetic resonance imaging (MRI). Studies were selected in duplicate, with data extraction and quality assessment verified by a second reviewer; risk of bias and evidence certainty were assessed using study design-specific tools and GRADE. Four RCTs and one cohort study (17 articles) were included: ERSPC, PLCO and CAP compared PSA screening with no screening, while STHLM3-MRI evaluated a risk-based test combined with MRI targeted biopsy. Meta-analysis showed 0.96 fewer prostate cancer deaths per 1000 individuals invited to screen, corresponding to a 12% relative reduction over 9.5–22 years (RR 0.88, 95% CI 0.81–0.95). One trial estimated 2.3% to 10.3% overdiagnosis over 10–14 years. Overall certainty of evidence was low or very low. PSA screening may offer a small mortality benefit, but uncertainty and variable harms limit confidence, underscoring the need for high-quality evidence, particularly for MRI and risk-based screening strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
- Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON M4N 3M5, Canada.
- Department of Family and Community Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON L8N 3Z5, Canada.
- Department of Oncology, McMaster University, Hamilton, ON L8V5C2, Canada.
- Independent Information Specialist, Ottawa, ON K1T 3Z2, Canada.
ORCID-Profile: Nicole Shaver, Faris Almoli, Andrew Loblaw, Xiaomei Yao, Becky Skidmore, Julian Little
Förderung
- Public Health Agency of Canada
Zitieren
APA
Bennett, A., Vyas, N., Shaver, N., Almoli, F., Kibret, T., Loblaw, A., Del Giudice, L., Yao, X., Skidmore, B., Brouwers, M., Little, J., & Moher, D. (2026). The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older: A Systematic Review. Current Oncology, 33(4), 199. https://doi.org/10.3390/curroncol33040199
Vancouver
Bennett A, Vyas N, Shaver N, Almoli F, Kibret T, Loblaw A, et al. The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older: A Systematic Review. Current Oncology. 2026;33(4):199. doi:10.3390/curroncol33040199
BibTeX
@article{Bennett2026,
author = {Bennett, Alexandria and Vyas, Niyati and Shaver, Nicole and Almoli, Faris and Kibret, Taddele and Loblaw, Andrew and Del Giudice, Lisa and Yao, Xiaomei and Skidmore, Becky and Brouwers, Melissa and Little, Julian and Moher, David},
title = {The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older: A Systematic Review},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {4},
pages = {199},
doi = {10.3390/curroncol33040199}
}
EUVIMED